emily oster glp 1 Our idea of a good time? Bringing our community together for real talk about GLP-1s, pregnancy, menopause, weight loss, and everything in between. #ICYMI, last week at Forty Carrots, and Dr. Emily Oster on science

Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)

Go to absolute failure every once in a while so you know what that actually feels like

Matoba, S., et al

Living with either medication: practical considerations Beyond the pharmacology and clinical trials, daily life on these medications differs in practical ways that matter

Yao Z, Liu L, Gao F, Rampitsch C, Reinecke DM, Ozga JA, Ayele BT (2012) Developmental and seed aging mediated regulation of antioxidative genes and differential expression of proteins during pre- and post-germinative phases in pea

Dosing errors have also been found with compounded tirzepatide, which many companies offer as an alternative to Mounjaro or Zepbound